智通财经APP讯，基石药业-B(02616)发布公告，于2025年4月11日，董事会决议根据首次公开发售后受限制股份奖励计划向95名受限制股份单位承授人授出合共675.72万份受限制股份单位。
在授予受限制股份单位承授人的合共675.72万份受限制股份单位中，包括授予一名董事的113.4万份受限制股份单位及授予公司雇员(包括高级管理层成员)的562.32万份受限制股份单位。
于2025年4月11日，董事会决议根据首次公开发售后雇员持股计划向95名购股权承授人授予合共1576.68万份购股权。
在授予购股权承授人的合共1576.68万份购股权中，包括授予一名董事的264.6万份购股权及授予公司雇员(包括高级管理层成员)的1312.08万份购股权。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.